Why Mitochondrial Gene Editing May Become the Next Platform Technology in Genetic Medicine One of the most interesting trends in biotechnology is that entirely new companies are increasingly being built around a single enabling platform rather than a single therapeutic asset. The recent launch of Primera Therapeutics is an excellent example. While headlines focused on the company's strategic collaboration with Cellectis and a partnership valued at up to $750 million, the more
